November 28, 2025 – Oxford UK
AlveoGene is pleased to provide an update on the progress of it’s pipeline of inhaled gene therapy development candidates targeting rare respiratory disease.
The Company has generated world leading pre-clinical data in SP-B surfactant protein deficiency, and AATD-Lung disease and provides additional Investor confidence in support of our current Series A financing.
This update is provided in the form of a short narrated presentation embedded below
For for information please visit www.alveogene.com